Talk:Combined oral contraceptive pill: Difference between revisions

Browse history interactively ← Previous edit Next edit →Content deleted Content addedVisual WikitextInline

Revision as of 18:06, 16 January 2022 editPrimeBOT (talk \| contribs)Bots2,048,549 editsm Task 24: template substitution following a TFD Tag: AWB ← Previous edit		Revision as of 00:13, 17 January 2022 edit undoLowercase sigmabot III (talk \| contribs)Bots, Template editors2,291,808 editsm Archiving 1 discussion(s) to Talk:Combined oral contraceptive pill/Archive 2) (botNext edit →
Line 31:		Line 31:

	{{small\|Above undated message substituted from ] by ] (]) 18:06, 16 January 2022 (UTC)}}		{{small\|Above undated message substituted from ] by ] (]) 18:06, 16 January 2022 (UTC)}}
	== Queen's University Medical Student Editing Initiative ==

	Hello,

	We are a group of medical students from Queen's University. We are working to improve this article over the next month and will be posting our planned changes on this talk page. We looking forward to working with the existing Misplaced Pages medical editing community to improve this article and share evidence. We welcome feedback and suggestions as we learn to edit. Thank you, ] (]) 20:19, 23 November 2020 (UTC)

	1. '''Side effects: '''We propose on inserting the following content under Section:Side Effects and Subsection:Common, “Additionally, taking the pill can be helpful in preventing pelvic inflammatory disease <ref>{{cite journal \|last1=Schindler \|first1=AE \|title=Non-contraceptive benefits of oral hormonal contraceptives. \|journal=International journal of endocrinology and metabolism \|date=2013 \|volume=11 \|issue=1 \|pages=41-7 \|doi=10.5812/ijem.4158 \|pmid=23853619}}</ref>",and removing "pelvic inflammatory disease" from the statement "On the other hand, the pills can sometimes improve conditions such as pelvic inflammatory disease, dysmenorrhea......".
	] (]) 20:53, 2 December 2020 (UTC)Chickensaladsandwich

	Under Section:Side Effects and Subsection:Common, we propose changing the final sentence of the second paragraph to include a reduced risk of endometrial cancer as well as ovarian cancer. The sentence would be "Use of oral contraceptives also reduces lifetime risk of ovarian and endometrial cancer." <ref>{{cite journal \|last1=Pragout \|first1=D \|last2=Laurence \|first2=V \|last3=Baffet \|first3=H \|last4=Raccah-Tebeka \|first4=B \|last5=Rousset-Jablonski \|first5=C \|title=. \|journal=Gynecologie, obstetrique, fertilite & senologie \|date=December 2018 \|volume=46 \|issue=12 \|pages=834-844 \|doi=10.1016/j.gofs.2018.10.010 \|pmid=30385358}}</ref> --] (]) 16:25, 3 December 2020 (UTC)Sarahliuu

	Under Section:Side Effects and Subsection:Heart and blood vessels, we propose changing the first sentence of the second paragraph to reflect an update to the Cochrane review that was cited for this claim. The sentence would be "While lower doses of estrogen in COC pills may have a lower risk of stroke and myocardial infarction compared to higher dose estrogen, users of low estrogen dose COC pills still have an increased risk compared to non-users."<ref>{{cite journal \|last1=Roach \|first1=RE \|last2=Helmerhorst \|first2=FM \|last3=Lijfering \|first3=WM \|last4=Stijnen \|first4=T \|last5=Algra \|first5=A \|last6=Dekkers \|first6=OM \|title=Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. \|journal=The Cochrane database of systematic reviews \|date=27 August 2015 \|issue=8 \|pages=CD011054 \|doi=10.1002/14651858.CD011054.pub2 \|pmid=26310586}}</ref> ] (]) 02:11, 4 December 2020 (UTC)

	{{reflist-talk}}
	2. '''Contraindications: '''Under Section:Contraindications we propose adding to the fourth sentence of the first paragraph so it reads "All COCP users have a small increase in the risk of venous thromboembolism compared with non-users; this risk is greatest within the first year of COCP use.<ref>{{cite journal \|last1=Black \|first1=A \|last2=Guilbert \|first2=E \|last3=Costescu \|first3=D \|last4=Dunn \|first4=S \|last5=Fisher \|first5=W \|last6=Kives \|first6=S \|last7=Mirosh \|first7=M \|last8=Norman \|first8=WV \|last9=Pymar \|first9=H \|last10=Reid \|first10=R \|last11=Roy \|first11=G \|last12=Varto \|first12=H \|last13=Waddington \|first13=A \|last14=Wagner \|first14=MS \|last15=Whelan \|first15=AM \|title=No. 329-Canadian Contraception Consensus Part 4 of 4 Chapter 9: Combined Hormonal Contraception. \|journal=Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC \|date=April 2017 \|volume=39 \|issue=4 \|pages=229-268.e5 \|doi=10.1016/j.jogc.2016.10.005 \|pmid=28413042}}</ref> Individuals with any pre-existing medical condition that also increases their risk for blood clots have a more significant increase in risk of thrombotic events with COCP use<ref>{{cite journal \|last1=Black \|first1=A \|last2=Guilbert \|first2=E \|last3=Costescu \|first3=D \|last4=Dunn \|first4=S \|last5=Fisher \|first5=W \|last6=Kives \|first6=S \|last7=Mirosh \|first7=M \|last8=Norman \|first8=WV \|last9=Pymar \|first9=H \|last10=Reid \|first10=R \|last11=Roy \|first11=G \|last12=Varto \|first12=H \|last13=Waddington \|first13=A \|last14=Wagner \|first14=MS \|last15=Whelan \|first15=AM \|title=No. 329-Canadian Contraception Consensus Part 4 of 4 Chapter 9: Combined Hormonal Contraception. \|journal=Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC \|date=April 2017 \|volume=39 \|issue=4 \|pages=229-268.e5 \|doi=10.1016/j.jogc.2016.10.005 \|pmid=28413042}}</ref>."] (]) 23:06, 3 December 2020 (UTC)(])

	Under Section: Contraindications, we propose to add to the contraindication already stated for women who are breastfeeding due to risks of blood clots by elaborating on the concerns about the transient risk of COCPs on breast milk production as well as clarify when COPCs are generally safe to use again by postpartum women breastfeeding or not. The additions would be "While studies have demonstrated conflicting results about the effects of COPCs on lactation duration and milk volume, there exist concerns about the transient risk of COCPs on breast milk production when breastfeeding is being established early postpartum.<ref>{{cite journal \|last1=Lopez \|first1=Laureen M \|last2=Grey \|first2=Thomas W \|last3=Stuebe \|first3=Alison M \|last4=Chen \|first4=Mario \|last5=Truitt \|first5=Sarah T \|last6=Gallo \|first6=Maria F \|title=Combined hormonal versus nonhormonal versus progestin-only contraception in lactation \|journal=Cochrane Database of Systematic Reviews \|date=20 March 2015 \|doi=10.1002/14651858.CD003988.pub2 \|url=https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003988.pub2/full}}</ref> Due to the stated risks and additional concerns on lactation, women who are breastfeeding are not advised to start COPCs until at least six weeks postpartum, while women who are not breastfeeding and have no other risks factors for blood clots may start COCPs after 21 days postpartum.<ref>{{cite book \|title=Medical eligibility criteria for contraceptive use. \|publisher=World Health Organization \|location=Geneva, Switzerland \|isbn=9789241549158 \|edition=Fifth}}</ref><ref>{{cite web \|title=Classifications for Combined Hormonal Contraceptives {{!}} CDC \|url=https://www.cdc.gov/reproductivehealth/contraception/mmwr/mec/appendixd.html \|website=www.cdc.gov \|publisher=Centers for Disease Control and Prevention \|language=en-us \|date=9 April 2020}}</ref>" ] (]) 08:39, 4 December 2020 (UTC)
	{{reflist-talk}}
	3. '''Role of placebo pills:''' Under Section: Role of placebo pills, we propose to add two sentences briefly detailing the supplementation of COCPs with folic acid. The following sentences will be added to the end of the paragraph: “As well, birth control pills, such as COCPs, are often fortified with folic acid as it is recommended to take folic acid supplementation months prior to pregnancy to decrease the likelihood of ] in infants.<ref>{{cite journal \|last1=Viswanathan \|first1=Meera \|last2=Treiman \|first2=Katherine \|last3=Kish Doto \|first3=Julia \|last4=Middleton \|first4=Jennifer C \|last5=Coker-Schwimmer \|first5=Emmanuel JL \|last6=Nicholson \|first6=Wanda K \|title=Folic Acid Supplementation: An Evidence Review for the U.S. Preventive Services Task Force \|journal=U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. \|date=Jan 2017 \|page=4-05214-EF-1 \|pmid=28151610}}</ref><ref>{{cite journal \|last1=Lassi \|first1=Zohra \|last2=Bhutta \|first2=Zulfiqar \|title=Clinical utility of folate-containing oral contraceptives \|journal=International Journal of Women's Health \|date=April 2012 \|issue=4 \|page=185-190 \|doi=10.2147/IJWH.S18611 \|pmid=22570577}}</ref> With folic acid fortification, people who have been taking COCPs for months before pregnancy may already have sufficient amounts.<ref>{{cite journal \|last1=Viswanathan \|first1=Meera \|last2=Treiman \|first2=Katherine \|last3=Kish Doto \|first3=Julia \|last4=Middleton \|first4=Jennifer C \|last5=Coker-Schwimmer \|first5=Emmanuel JL \|last6=Nicholson \|first6=Wanda K \|title=Folic Acid Supplementation: An Evidence Review for the U.S. Preventive Services Task Force \|journal=U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. \|date=Jan 2017 \|page=4-05214-EF-1 \|pmid=28151610}}</ref><ref>{{cite journal \|last1=Lassi \|first1=Zohra \|last2=Bhutta \|first2=Zulfiqar \|title=Clinical utility of folate-containing oral contraceptives \|journal=International Journal of Women's Health \|date=April 2012 \|issue=4 \|page=185-190 \|doi=10.2147/IJWH.S18611 \|pmid=22570577}}</ref>” ] (]) 19:10, 4 December 2020 (UTC)
	{{reflist-talk}}
	:'''Thanks for sharing these improvements. Note {{Ping\|Smaho22\|sbk1998}} Multiple use of the same reference- tech tip. When you add your references while editing, you can see the options "automatic... Manual... Re-use". The first time you add the citation (if it is not already used in an article, click "automatic" and add your PMID, DOI, or website, then click "generate" to fill the template. The second time you want to use the same citation in an article, click "reusue" and search for your citation in the list. This adds in the a,b,c versus duplicating the citation in the list. If possible, practice this in your sandbox before editing live on Monday'''.] (]) 16:57, 7 December 2020 (UTC)

Revision as of 00:13, 17 January 2022

This is the talk page for discussing improvements to the Combined oral contraceptive pill article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Misplaced Pages? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Archives: 1, 2Auto-archiving period: 12 months

Template:Vital article

A fact from this article was featured on Misplaced Pages's Main Page in the On this day section on May 9, 2013, May 9, 2016, and May 9, 2020.

This article has not yet been rated on Misplaced Pages's content assessment scale.
It is of interest to the following WikiProjects:

Please add the quality rating to the {{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details.

Women's Health Top‑importance

	This article is within the scope of WikiProject Women's Health, a collaborative effort to improve the coverage of Women's Health on Misplaced Pages. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.Women's HealthWikipedia:WikiProject Women's HealthTemplate:WikiProject Women's Healthwomen's health
Top	This article has been rated as Top-importance on the importance scale.

Please add the quality rating to the {{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details.

Medicine: Reproductive High‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Misplaced Pages talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine
High	This article has been rated as High-importance on the project's importance scale.
	This article is supported by the Reproductive medicine task force (assessed as High-importance).

Please add the quality rating to the {{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details.

Sexology and sexuality Top‑importance

	Human sexuality portal This article is within the scope of WikiProject Sexology and sexuality, a collaborative effort to improve the coverage of human sexuality on Misplaced Pages. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.Sexology and sexualityWikipedia:WikiProject Sexology and sexualityTemplate:WikiProject Sexology and sexualitySexology and sexuality
Top	This article has been rated as Top-importance on the project's importance scale.

Please add the quality rating to the {{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details.

Pharmacology High‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Misplaced Pages. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology
High	This article has been rated as High-importance on the project's importance scale.

Please add the quality rating to the {{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details.

Women's History Mid‑importance

	History portal This article is within the scope of WikiProject Women's History, a collaborative effort to improve the coverage of Women's history and related articles on Misplaced Pages. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.Women's HistoryWikipedia:WikiProject Women's HistoryTemplate:WikiProject Women's HistoryWomen's History
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Misplaced Pages's health content are defined in the guideline Misplaced Pages:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Combined oral contraceptive pill.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Archives

Archive before COCP renaming
Archive 1

This page has archives. Sections older than 365 days may be automatically archived by Lowercase sigmabot III when more than 1 section is present.

This article was the subject of a Wiki Education Foundation-supported course assignment, between 8 January 2019 and 16 April 2019. Further details are available on the course page. Student editor(s): Raachelc (article contribs). Peer reviewers: Raachelc. This article was the subject of a Wiki Education Foundation-supported course assignment, between 1 July 2019 and 23 August 2019. Further details are available on the course page. Student editor(s): Davdang, Cindytrac, Gabidriller, RwengUCSF, AMONGxicillin (article contribs).

Wiki Education Foundation-supported course assignment

This article is or was the subject of a Wiki Education Foundation-supported course assignment. Further details are available on the course page. Student editor(s): DOtter. Peer reviewers: Wendi.gu.

Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 18:06, 16 January 2022 (UTC)

Categories:

Revision as of 18:06, 16 January 2022 editPrimeBOT (talk \| contribs)Bots2,048,549 editsm Task 24: template substitution following a TFD Tag: AWB ← Previous edit		Revision as of 00:13, 17 January 2022 edit undoLowercase sigmabot III (talk \| contribs)Bots, Template editors2,291,808 editsm Archiving 1 discussion(s) to Talk:Combined oral contraceptive pill/Archive 2) (botNext edit →
Line 31:		Line 31:

	{{small\|Above undated message substituted from ] by ] (]) 18:06, 16 January 2022 (UTC)}}		{{small\|Above undated message substituted from ] by ] (]) 18:06, 16 January 2022 (UTC)}}
	== Queen's University Medical Student Editing Initiative ==

	Hello,

	We are a group of medical students from Queen's University. We are working to improve this article over the next month and will be posting our planned changes on this talk page. We looking forward to working with the existing Misplaced Pages medical editing community to improve this article and share evidence. We welcome feedback and suggestions as we learn to edit. Thank you, ] (]) 20:19, 23 November 2020 (UTC)

	1. '''Side effects: '''We propose on inserting the following content under Section:Side Effects and Subsection:Common, “Additionally, taking the pill can be helpful in preventing pelvic inflammatory disease <ref>{{cite journal \|last1=Schindler \|first1=AE \|title=Non-contraceptive benefits of oral hormonal contraceptives. \|journal=International journal of endocrinology and metabolism \|date=2013 \|volume=11 \|issue=1 \|pages=41-7 \|doi=10.5812/ijem.4158 \|pmid=23853619}}</ref>",and removing "pelvic inflammatory disease" from the statement "On the other hand, the pills can sometimes improve conditions such as pelvic inflammatory disease, dysmenorrhea......".
	] (]) 20:53, 2 December 2020 (UTC)Chickensaladsandwich

	Under Section:Side Effects and Subsection:Common, we propose changing the final sentence of the second paragraph to include a reduced risk of endometrial cancer as well as ovarian cancer. The sentence would be "Use of oral contraceptives also reduces lifetime risk of ovarian and endometrial cancer." <ref>{{cite journal \|last1=Pragout \|first1=D \|last2=Laurence \|first2=V \|last3=Baffet \|first3=H \|last4=Raccah-Tebeka \|first4=B \|last5=Rousset-Jablonski \|first5=C \|title=. \|journal=Gynecologie, obstetrique, fertilite & senologie \|date=December 2018 \|volume=46 \|issue=12 \|pages=834-844 \|doi=10.1016/j.gofs.2018.10.010 \|pmid=30385358}}</ref> --] (]) 16:25, 3 December 2020 (UTC)Sarahliuu

	Under Section:Side Effects and Subsection:Heart and blood vessels, we propose changing the first sentence of the second paragraph to reflect an update to the Cochrane review that was cited for this claim. The sentence would be "While lower doses of estrogen in COC pills may have a lower risk of stroke and myocardial infarction compared to higher dose estrogen, users of low estrogen dose COC pills still have an increased risk compared to non-users."<ref>{{cite journal \|last1=Roach \|first1=RE \|last2=Helmerhorst \|first2=FM \|last3=Lijfering \|first3=WM \|last4=Stijnen \|first4=T \|last5=Algra \|first5=A \|last6=Dekkers \|first6=OM \|title=Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. \|journal=The Cochrane database of systematic reviews \|date=27 August 2015 \|issue=8 \|pages=CD011054 \|doi=10.1002/14651858.CD011054.pub2 \|pmid=26310586}}</ref> ] (]) 02:11, 4 December 2020 (UTC)

	{{reflist-talk}}
	2. '''Contraindications: '''Under Section:Contraindications we propose adding to the fourth sentence of the first paragraph so it reads "All COCP users have a small increase in the risk of venous thromboembolism compared with non-users; this risk is greatest within the first year of COCP use.<ref>{{cite journal \|last1=Black \|first1=A \|last2=Guilbert \|first2=E \|last3=Costescu \|first3=D \|last4=Dunn \|first4=S \|last5=Fisher \|first5=W \|last6=Kives \|first6=S \|last7=Mirosh \|first7=M \|last8=Norman \|first8=WV \|last9=Pymar \|first9=H \|last10=Reid \|first10=R \|last11=Roy \|first11=G \|last12=Varto \|first12=H \|last13=Waddington \|first13=A \|last14=Wagner \|first14=MS \|last15=Whelan \|first15=AM \|title=No. 329-Canadian Contraception Consensus Part 4 of 4 Chapter 9: Combined Hormonal Contraception. \|journal=Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC \|date=April 2017 \|volume=39 \|issue=4 \|pages=229-268.e5 \|doi=10.1016/j.jogc.2016.10.005 \|pmid=28413042}}</ref> Individuals with any pre-existing medical condition that also increases their risk for blood clots have a more significant increase in risk of thrombotic events with COCP use<ref>{{cite journal \|last1=Black \|first1=A \|last2=Guilbert \|first2=E \|last3=Costescu \|first3=D \|last4=Dunn \|first4=S \|last5=Fisher \|first5=W \|last6=Kives \|first6=S \|last7=Mirosh \|first7=M \|last8=Norman \|first8=WV \|last9=Pymar \|first9=H \|last10=Reid \|first10=R \|last11=Roy \|first11=G \|last12=Varto \|first12=H \|last13=Waddington \|first13=A \|last14=Wagner \|first14=MS \|last15=Whelan \|first15=AM \|title=No. 329-Canadian Contraception Consensus Part 4 of 4 Chapter 9: Combined Hormonal Contraception. \|journal=Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC \|date=April 2017 \|volume=39 \|issue=4 \|pages=229-268.e5 \|doi=10.1016/j.jogc.2016.10.005 \|pmid=28413042}}</ref>."] (]) 23:06, 3 December 2020 (UTC)(])

	Under Section: Contraindications, we propose to add to the contraindication already stated for women who are breastfeeding due to risks of blood clots by elaborating on the concerns about the transient risk of COCPs on breast milk production as well as clarify when COPCs are generally safe to use again by postpartum women breastfeeding or not. The additions would be "While studies have demonstrated conflicting results about the effects of COPCs on lactation duration and milk volume, there exist concerns about the transient risk of COCPs on breast milk production when breastfeeding is being established early postpartum.<ref>{{cite journal \|last1=Lopez \|first1=Laureen M \|last2=Grey \|first2=Thomas W \|last3=Stuebe \|first3=Alison M \|last4=Chen \|first4=Mario \|last5=Truitt \|first5=Sarah T \|last6=Gallo \|first6=Maria F \|title=Combined hormonal versus nonhormonal versus progestin-only contraception in lactation \|journal=Cochrane Database of Systematic Reviews \|date=20 March 2015 \|doi=10.1002/14651858.CD003988.pub2 \|url=https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003988.pub2/full}}</ref> Due to the stated risks and additional concerns on lactation, women who are breastfeeding are not advised to start COPCs until at least six weeks postpartum, while women who are not breastfeeding and have no other risks factors for blood clots may start COCPs after 21 days postpartum.<ref>{{cite book \|title=Medical eligibility criteria for contraceptive use. \|publisher=World Health Organization \|location=Geneva, Switzerland \|isbn=9789241549158 \|edition=Fifth}}</ref><ref>{{cite web \|title=Classifications for Combined Hormonal Contraceptives {{!}} CDC \|url=https://www.cdc.gov/reproductivehealth/contraception/mmwr/mec/appendixd.html \|website=www.cdc.gov \|publisher=Centers for Disease Control and Prevention \|language=en-us \|date=9 April 2020}}</ref>" ] (]) 08:39, 4 December 2020 (UTC)
	{{reflist-talk}}
	3. '''Role of placebo pills:''' Under Section: Role of placebo pills, we propose to add two sentences briefly detailing the supplementation of COCPs with folic acid. The following sentences will be added to the end of the paragraph: “As well, birth control pills, such as COCPs, are often fortified with folic acid as it is recommended to take folic acid supplementation months prior to pregnancy to decrease the likelihood of ] in infants.<ref>{{cite journal \|last1=Viswanathan \|first1=Meera \|last2=Treiman \|first2=Katherine \|last3=Kish Doto \|first3=Julia \|last4=Middleton \|first4=Jennifer C \|last5=Coker-Schwimmer \|first5=Emmanuel JL \|last6=Nicholson \|first6=Wanda K \|title=Folic Acid Supplementation: An Evidence Review for the U.S. Preventive Services Task Force \|journal=U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. \|date=Jan 2017 \|page=4-05214-EF-1 \|pmid=28151610}}</ref><ref>{{cite journal \|last1=Lassi \|first1=Zohra \|last2=Bhutta \|first2=Zulfiqar \|title=Clinical utility of folate-containing oral contraceptives \|journal=International Journal of Women's Health \|date=April 2012 \|issue=4 \|page=185-190 \|doi=10.2147/IJWH.S18611 \|pmid=22570577}}</ref> With folic acid fortification, people who have been taking COCPs for months before pregnancy may already have sufficient amounts.<ref>{{cite journal \|last1=Viswanathan \|first1=Meera \|last2=Treiman \|first2=Katherine \|last3=Kish Doto \|first3=Julia \|last4=Middleton \|first4=Jennifer C \|last5=Coker-Schwimmer \|first5=Emmanuel JL \|last6=Nicholson \|first6=Wanda K \|title=Folic Acid Supplementation: An Evidence Review for the U.S. Preventive Services Task Force \|journal=U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. \|date=Jan 2017 \|page=4-05214-EF-1 \|pmid=28151610}}</ref><ref>{{cite journal \|last1=Lassi \|first1=Zohra \|last2=Bhutta \|first2=Zulfiqar \|title=Clinical utility of folate-containing oral contraceptives \|journal=International Journal of Women's Health \|date=April 2012 \|issue=4 \|page=185-190 \|doi=10.2147/IJWH.S18611 \|pmid=22570577}}</ref>” ] (]) 19:10, 4 December 2020 (UTC)
	{{reflist-talk}}
	:'''Thanks for sharing these improvements. Note {{Ping\|Smaho22\|sbk1998}} Multiple use of the same reference- tech tip. When you add your references while editing, you can see the options "automatic... Manual... Re-use". The first time you add the citation (if it is not already used in an article, click "automatic" and add your PMID, DOI, or website, then click "generate" to fill the template. The second time you want to use the same citation in an article, click "reusue" and search for your citation in the list. This adds in the a,b,c versus duplicating the citation in the list. If possible, practice this in your sandbox before editing live on Monday'''.] (]) 16:57, 7 December 2020 (UTC)